We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Mesothelioma Differentiated from Carcinomas in Lung or Pleura

By LabMedica International staff writers
Posted on 22 Jun 2011
A microRNA-based molecular diagnostic tool accurately differentiates malignant pleural mesothelioma from other carcinomas in the lung and pleura.

Unlike the tests currently available, miRview meso is a microRNA-based molecular diagnostic tool that provides a differential diagnosis with accuracy, simple interpretation, and routine sample preparation.

The miRview meso assay uses quantitative real-time polymerase chain reaction (qRT-PCR) to determine the expression of microRNA in tumor tissue. More...
The sensitivity and specificity of this assay have been shown to be 100% and 94%, respectively.

The assay is based on formalin-fixed paraffin-embedded (FFPE) tumor samples, the current standard for preserving tumors in the postoperative setting. FFPE samples require minimal preparation to be analyzed by and can be easily shipped via any air courier.

The advantage of microRNAs as biomarkers lies in their high tissue specificity, and their stability in the most routine preservation methods for biopsies, including FFPE block tissue and fine needle aspirate (FNA) cell blocks. It has been suggested that their small size (19 to 21 nucleotides) enables them to remain intact in FFPE blocks, as opposed to messenger RNA (mRNA), which tends to degrade rapidly. In addition, early preclinical data has shown that by controlling the levels of specific microRNAs, cancer cell growth may be reduced.

Rosetta Genomics (Rehovot, Israel), the developer and provider of microRNA-based molecular diagnostic tests, has signed an exclusive marketing agreement with PACE Claims Services, a subsidiary of Navigant Consulting, Inc. (Chicago, IL, USA) to provide educational and marketing services on behalf of Rosetta Genomics' miRview meso diagnostic test to defendants and insurers in mesothelioma legal cases worldwide is a market leader in asbestos claims administration.

Related Links:
Rosetta Genomics
PACE Claims Services
Navigant Consulting, Inc.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.